Lymphoplasmacytic lymphoma/immunocytoma

Towards a disease-targeted treatment?

M. Clavio, S. Quintino, C. Venturino, F. Ballerini, R. Varaldo, S. Gatto, V. Galbusera, A. Garrone, R. Grasso, L. Canepa, M. Miglino, I. Pierri, M. Gobbi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Lymphoplasmacytic-lymphoplasmacytoid lymphoma (LPL) / Waldenstrom's macroglobulinemia (WM) or immunocytoma (IMC) consists of diffuse proliferation of small mature B lymphocytes, plasmacytoid lymphocytes, and plasma-cells. The nosographic definition includes the lack of histological, immunophenotypic, cytogenetic, and molecular markers considered specific of other types of lymphoma. The cells show surface Ig (usually IgM), B-cell-associated antigens and display the CD5-, CD23- and CD10- phenotype, which allows for differential diagnosis from B-CLL and mantle cell lymphoma, t(9;14)(p13;q32) chromosomal translocation has been found in 50% of all LPL cases. The cytogenetic rearrangement juxtaposes the PAX-5 gene, which encodes for an essential transcription factor for B-cell proliferation and differention, to the Ig heavy chain gene. The combination of chlorambucil and prednisone holds as the standard treatment and seems to guarantee good control of the disease in most patients. Similar therapeutic results have been described with the combination of cyclophosphamide, vincristine, prednisone with (CHOP) or without doxorubicin (CVP), or with a combination of other alkylating agents and prednisone. Nucleoside analogues, alone or in combination with alkylating agents and anthracyclines, provide good salvage therapy for IMC and being increasingly employed as first line therapy. In a multicentric European trial Foran et al. administered the chimeric anti-CD20-monoclonal antibody (Rituximab) to 28 patients with previously treated IMC. Seven out of 25 evaluable patients (28%) achieved a partial response. Byrd et al. examined the outcome of 7 previously treated WM patients who received weekly infusions of rituximab (375 mg/m2). Therapy was well tolerated by all patients, and there was no decrease in cellular immune function, or significant infectious morbidity. Partial responses were noted in three of these patients, including two with fludarabine-refractory disease. These data suggest that rituximab exerts clinical activity on heavily pre-treated patients with WM. Furthermore, Weide et al. first reported that WM-associated polyneuropathy can be treated effectively with a combination of chemotherapy and the anti-CD20 monoclonal antibody rituximab. Most published trials exploring the efficacy of high dose treatment as salvage therapy for relapsed or refractory low grade non Hodgkin's lymphoma have included prevalently follicular or lymphocytic lymphomas. In selected high risk patients radioimmunotherapy with autologous stem-cell rescue, and myeloablative therapy followed either by autologous stem cell transplantation (SCT) or allogeneic SCT might represent an alternative strategy.

Original languageEnglish
Pages (from-to)351-358
Number of pages8
JournalJournal of Experimental and Clinical Cancer Research
Volume20
Issue number3
Publication statusPublished - 2001

Fingerprint

Waldenstrom Macroglobulinemia
Lymphoma
Prednisone
Salvage Therapy
B-Lymphocytes
Alkylating Agents
Stem Cell Transplantation
Therapeutics
Cytogenetics
Non-Hodgkin's Lymphoma
CD5 Antigens
Monoclonal Antibodies
Radioimmunotherapy
Chlorambucil
Mantle-Cell Lymphoma
Neprilysin
Immunoglobulin Heavy Chains
Genetic Translocation
Follicular Lymphoma
Polyneuropathies

Keywords

  • Immunocytoma
  • Lymphoplasmacytic-Lymphoplasmacytoid lymphoma
  • Rituximab
  • Waldenstrom's macroglobulinemia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lymphoplasmacytic lymphoma/immunocytoma : Towards a disease-targeted treatment? / Clavio, M.; Quintino, S.; Venturino, C.; Ballerini, F.; Varaldo, R.; Gatto, S.; Galbusera, V.; Garrone, A.; Grasso, R.; Canepa, L.; Miglino, M.; Pierri, I.; Gobbi, M.

In: Journal of Experimental and Clinical Cancer Research, Vol. 20, No. 3, 2001, p. 351-358.

Research output: Contribution to journalArticle

Clavio, M, Quintino, S, Venturino, C, Ballerini, F, Varaldo, R, Gatto, S, Galbusera, V, Garrone, A, Grasso, R, Canepa, L, Miglino, M, Pierri, I & Gobbi, M 2001, 'Lymphoplasmacytic lymphoma/immunocytoma: Towards a disease-targeted treatment?', Journal of Experimental and Clinical Cancer Research, vol. 20, no. 3, pp. 351-358.
Clavio, M. ; Quintino, S. ; Venturino, C. ; Ballerini, F. ; Varaldo, R. ; Gatto, S. ; Galbusera, V. ; Garrone, A. ; Grasso, R. ; Canepa, L. ; Miglino, M. ; Pierri, I. ; Gobbi, M. / Lymphoplasmacytic lymphoma/immunocytoma : Towards a disease-targeted treatment?. In: Journal of Experimental and Clinical Cancer Research. 2001 ; Vol. 20, No. 3. pp. 351-358.
@article{c00fc44e0dc344eba8b52ba07222b5e1,
title = "Lymphoplasmacytic lymphoma/immunocytoma: Towards a disease-targeted treatment?",
abstract = "Lymphoplasmacytic-lymphoplasmacytoid lymphoma (LPL) / Waldenstrom's macroglobulinemia (WM) or immunocytoma (IMC) consists of diffuse proliferation of small mature B lymphocytes, plasmacytoid lymphocytes, and plasma-cells. The nosographic definition includes the lack of histological, immunophenotypic, cytogenetic, and molecular markers considered specific of other types of lymphoma. The cells show surface Ig (usually IgM), B-cell-associated antigens and display the CD5-, CD23- and CD10- phenotype, which allows for differential diagnosis from B-CLL and mantle cell lymphoma, t(9;14)(p13;q32) chromosomal translocation has been found in 50{\%} of all LPL cases. The cytogenetic rearrangement juxtaposes the PAX-5 gene, which encodes for an essential transcription factor for B-cell proliferation and differention, to the Ig heavy chain gene. The combination of chlorambucil and prednisone holds as the standard treatment and seems to guarantee good control of the disease in most patients. Similar therapeutic results have been described with the combination of cyclophosphamide, vincristine, prednisone with (CHOP) or without doxorubicin (CVP), or with a combination of other alkylating agents and prednisone. Nucleoside analogues, alone or in combination with alkylating agents and anthracyclines, provide good salvage therapy for IMC and being increasingly employed as first line therapy. In a multicentric European trial Foran et al. administered the chimeric anti-CD20-monoclonal antibody (Rituximab) to 28 patients with previously treated IMC. Seven out of 25 evaluable patients (28{\%}) achieved a partial response. Byrd et al. examined the outcome of 7 previously treated WM patients who received weekly infusions of rituximab (375 mg/m2). Therapy was well tolerated by all patients, and there was no decrease in cellular immune function, or significant infectious morbidity. Partial responses were noted in three of these patients, including two with fludarabine-refractory disease. These data suggest that rituximab exerts clinical activity on heavily pre-treated patients with WM. Furthermore, Weide et al. first reported that WM-associated polyneuropathy can be treated effectively with a combination of chemotherapy and the anti-CD20 monoclonal antibody rituximab. Most published trials exploring the efficacy of high dose treatment as salvage therapy for relapsed or refractory low grade non Hodgkin's lymphoma have included prevalently follicular or lymphocytic lymphomas. In selected high risk patients radioimmunotherapy with autologous stem-cell rescue, and myeloablative therapy followed either by autologous stem cell transplantation (SCT) or allogeneic SCT might represent an alternative strategy.",
keywords = "Immunocytoma, Lymphoplasmacytic-Lymphoplasmacytoid lymphoma, Rituximab, Waldenstrom's macroglobulinemia",
author = "M. Clavio and S. Quintino and C. Venturino and F. Ballerini and R. Varaldo and S. Gatto and V. Galbusera and A. Garrone and R. Grasso and L. Canepa and M. Miglino and I. Pierri and M. Gobbi",
year = "2001",
language = "English",
volume = "20",
pages = "351--358",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",
number = "3",

}

TY - JOUR

T1 - Lymphoplasmacytic lymphoma/immunocytoma

T2 - Towards a disease-targeted treatment?

AU - Clavio, M.

AU - Quintino, S.

AU - Venturino, C.

AU - Ballerini, F.

AU - Varaldo, R.

AU - Gatto, S.

AU - Galbusera, V.

AU - Garrone, A.

AU - Grasso, R.

AU - Canepa, L.

AU - Miglino, M.

AU - Pierri, I.

AU - Gobbi, M.

PY - 2001

Y1 - 2001

N2 - Lymphoplasmacytic-lymphoplasmacytoid lymphoma (LPL) / Waldenstrom's macroglobulinemia (WM) or immunocytoma (IMC) consists of diffuse proliferation of small mature B lymphocytes, plasmacytoid lymphocytes, and plasma-cells. The nosographic definition includes the lack of histological, immunophenotypic, cytogenetic, and molecular markers considered specific of other types of lymphoma. The cells show surface Ig (usually IgM), B-cell-associated antigens and display the CD5-, CD23- and CD10- phenotype, which allows for differential diagnosis from B-CLL and mantle cell lymphoma, t(9;14)(p13;q32) chromosomal translocation has been found in 50% of all LPL cases. The cytogenetic rearrangement juxtaposes the PAX-5 gene, which encodes for an essential transcription factor for B-cell proliferation and differention, to the Ig heavy chain gene. The combination of chlorambucil and prednisone holds as the standard treatment and seems to guarantee good control of the disease in most patients. Similar therapeutic results have been described with the combination of cyclophosphamide, vincristine, prednisone with (CHOP) or without doxorubicin (CVP), or with a combination of other alkylating agents and prednisone. Nucleoside analogues, alone or in combination with alkylating agents and anthracyclines, provide good salvage therapy for IMC and being increasingly employed as first line therapy. In a multicentric European trial Foran et al. administered the chimeric anti-CD20-monoclonal antibody (Rituximab) to 28 patients with previously treated IMC. Seven out of 25 evaluable patients (28%) achieved a partial response. Byrd et al. examined the outcome of 7 previously treated WM patients who received weekly infusions of rituximab (375 mg/m2). Therapy was well tolerated by all patients, and there was no decrease in cellular immune function, or significant infectious morbidity. Partial responses were noted in three of these patients, including two with fludarabine-refractory disease. These data suggest that rituximab exerts clinical activity on heavily pre-treated patients with WM. Furthermore, Weide et al. first reported that WM-associated polyneuropathy can be treated effectively with a combination of chemotherapy and the anti-CD20 monoclonal antibody rituximab. Most published trials exploring the efficacy of high dose treatment as salvage therapy for relapsed or refractory low grade non Hodgkin's lymphoma have included prevalently follicular or lymphocytic lymphomas. In selected high risk patients radioimmunotherapy with autologous stem-cell rescue, and myeloablative therapy followed either by autologous stem cell transplantation (SCT) or allogeneic SCT might represent an alternative strategy.

AB - Lymphoplasmacytic-lymphoplasmacytoid lymphoma (LPL) / Waldenstrom's macroglobulinemia (WM) or immunocytoma (IMC) consists of diffuse proliferation of small mature B lymphocytes, plasmacytoid lymphocytes, and plasma-cells. The nosographic definition includes the lack of histological, immunophenotypic, cytogenetic, and molecular markers considered specific of other types of lymphoma. The cells show surface Ig (usually IgM), B-cell-associated antigens and display the CD5-, CD23- and CD10- phenotype, which allows for differential diagnosis from B-CLL and mantle cell lymphoma, t(9;14)(p13;q32) chromosomal translocation has been found in 50% of all LPL cases. The cytogenetic rearrangement juxtaposes the PAX-5 gene, which encodes for an essential transcription factor for B-cell proliferation and differention, to the Ig heavy chain gene. The combination of chlorambucil and prednisone holds as the standard treatment and seems to guarantee good control of the disease in most patients. Similar therapeutic results have been described with the combination of cyclophosphamide, vincristine, prednisone with (CHOP) or without doxorubicin (CVP), or with a combination of other alkylating agents and prednisone. Nucleoside analogues, alone or in combination with alkylating agents and anthracyclines, provide good salvage therapy for IMC and being increasingly employed as first line therapy. In a multicentric European trial Foran et al. administered the chimeric anti-CD20-monoclonal antibody (Rituximab) to 28 patients with previously treated IMC. Seven out of 25 evaluable patients (28%) achieved a partial response. Byrd et al. examined the outcome of 7 previously treated WM patients who received weekly infusions of rituximab (375 mg/m2). Therapy was well tolerated by all patients, and there was no decrease in cellular immune function, or significant infectious morbidity. Partial responses were noted in three of these patients, including two with fludarabine-refractory disease. These data suggest that rituximab exerts clinical activity on heavily pre-treated patients with WM. Furthermore, Weide et al. first reported that WM-associated polyneuropathy can be treated effectively with a combination of chemotherapy and the anti-CD20 monoclonal antibody rituximab. Most published trials exploring the efficacy of high dose treatment as salvage therapy for relapsed or refractory low grade non Hodgkin's lymphoma have included prevalently follicular or lymphocytic lymphomas. In selected high risk patients radioimmunotherapy with autologous stem-cell rescue, and myeloablative therapy followed either by autologous stem cell transplantation (SCT) or allogeneic SCT might represent an alternative strategy.

KW - Immunocytoma

KW - Lymphoplasmacytic-Lymphoplasmacytoid lymphoma

KW - Rituximab

KW - Waldenstrom's macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=0034769369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034769369&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 351

EP - 358

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 3

ER -